REFERENCES

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Omalizumab (Xolair): Treatment of Adults and Adolescents (12 Years of Age and above) with Chronic Idiopathic Urticaria [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug.

Omalizumab (Xolair): Treatment of Adults and Adolescents (12 Years of Age and above) with Chronic Idiopathic Urticaria [Internet].

Show details

Contents

< Prev Next >

REFERENCES

1.: McCormack PL. Omalizumab: a review of its use in patients with chronic spontaneous urticaria. Drugs. 2014 Sep;74(14):1693–1699. [PubMed: 25217402]
2.: Kaplan AP, Popov TA. Biologic agents and the therapy of chronic spontaneous urticaria. Curr Opin Allergy Clin Immunol. 2014 Aug;14(4):347–353. [PubMed: 24936849]
3.: Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy. 2011 Mar;66(3):317–330. [PubMed: 21083565]
4.: Weller K, Altrichter S, Ardelean E, Krause K, Magerl M, Metz M, et al. Chronic urticaria. Prevalence, course, prognostic factors and impact. Hautarzt. 2010 Sep;61(9):750–757. [PubMed: 20694454]
5.: Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2014 Jul;69(7):e1–e29. [PubMed: 24898678]
6.: Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014 Jul;69(7):868–887. [PubMed: 24785199]
7.: U.S. Food and Drug Administration [Internet]. Silver Spring (MD): U.S. Food and Drug Administration. Xolair (omalizumab): Drug safety communication - Slightly elevated risk of cardiovascular and cerebrovascular serious adverse events. Sep 26, 2014. [cited 2015 Feb 4]. Available from: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm416408.htm.
8.: ^PRXolair^® (omalizumab): sterile powder for reconstitution 150mg vial [product monograph]. Dorval (QC): Novartis Pharmaceuticals Canada Inc; Aug 26, 2014.
9.: Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014 Sep;134(3):560–567. [PubMed: 24679845]
10.: Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014 May;133(5):1270–1277. [PubMed: 24766875]
11.: Common Drug Review. Indication: adults and adolescents (>12 years of age) with moderate to severe persistent asthma. [Internet]. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment; 2006. [cited 2015 Feb 4]. Omalizumab (Xolair^® - Novartis Pharmaceuticals Canada Inc.). (CEDEC final recommendation). Available from: www.cadth.ca/media/cdr/complete/cdr_complete_Xolair_March7-06.pdf.
12.: Reactine^® Cetirizine hydrochloride tablets, 5 mg, 10 mg; Reactine^® Chewable Tablets, Cetirizine hydrochloride tablets (chewable), 5 mg, 10 mg; Reactine^® Fast Melt™ Junior, Cetirizine Hydrochloride Orally Disintegrating Tablets, 10 mg; Reactine^® Allergy Liquid Gels, Cetirizine hydrochloride capsules, 10 mg; Reactine^® Cetirizine hydrochloride syrup, 5 mg/5 mL; ^PrReactine^® 20 mg Tablet, Cetirizine hydrochloride tablets [product monograph]. Markham (ON): McNeil Consumer Healthcare; Jun 11, 2014.
13.: ^PRClaritin^® Loratadine Tablets USP, 10 mg; Claritin® Rapid Dissolve Loratadine Orally Disintegrating Tablets USP, 5 mg Loratadine Orally Disintegrating Tablets USP, 10 mg; Claritin Kisd® Loratadine Oral Solution USP, 1 mg/mL [product monograph]. Mississauga (ON): Bayer Inc; Dec 17, 2014.
14.: Aerius^® Desloratadine Tablet 5 mg, Desloratadine Syrup 0.5 mg/mL; Aerius Kids^® Desloratadine Syrup 0.5 mg/mLL [product monograph]. Mississauga (ON): Bayer Inc; Dec 4, 2014.
15.: Allegra^® fexofenadine hydrochloride, 60 mg capsules; Allegra^® 12 Hour fexofenadine hydrochloride, 60 mg Tablets; Allegra^® 24 Hour fexofenadine hydrochloride, 120 mg Tablets [product monograph]. Laval (QC): Sanofi-Aventis Canada Inc; Sep 8, 2006.
16.: Saini SS, Bindslev-Jensen C, Maurer M, Grob J, Baskan EB, Bradley MS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on G1-Antihistamines: A randomized, placebo-controlled study. J Invest Dermatol. 2014 Aug [PubMed: 25501032]
17.: Maurer M, Rosen K, Hsieh H, Saini SS, Gratten C, Gimenez-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013 Mar;368(10):924–935. [PubMed: 23432142]
18.: Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. Journal of Allergy & Clinical Immunology. 2013 Jul;132(1):101–109. [PubMed: 23810097]
19.: CDR submission: ^PRXolair^® (omalizumab), 150mg sterile powder for reconstitution. Company: Novartis Pharmaceuticals Canada Inc [CONFIDENTIAL manufacturer's submission]. Dorval (QC): Novartis Pharmaceuticals Canada Inc; 2014.
20.: A phase III, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of Xolair® (omalizumab) in patients with chronic idiopathic urticaria (CIU) who remain symptomatic despite antihistamine treatment (H1) [CONFIDENTIAL internal manufacturer's report]. San Francisco (CA): Genentech Inc; 2013. Final clinical study report: 1054397 (Protocol Q4881g).
21.: A phase III, multicenter, randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy, response duration and safety of Xolair® (omalizumab) in patients with chronic idiopathic urticaria (CIU) who remain symptomatic despite antihistamine treatment (H1) [CONFIDENTIAL internal manufacturer's report]. San Francisco (CA): Genentech Inc; 2013. Final clinical study report: 1053093 (Protocol Q4882g).
22.: A phase III, multicenter, randomized, double-blind, placebo-controlled safety study of Xolair (omalizumab) in patients with chronic idiopathic urticaria (CIU) who remain symptomatic despite treatment with H1 antihistamines, H2 blockers, and/or leukotriene receptor antagonists [CONFIDENTIAL internal manufacturer's report]. San Francisco (CA): Genentech Inc; 2013. Final clinical study report: 1054065 (Protocol Q4883g).
23.: Health Canada reviewer's report: Xolair (omalizumab) [CONFIDENTIAL internal report]. Ottawa: Health Products and Food Branch, Health Canada; 2014.
24.: Mathias SD, Dreskin SC, Kaplan A, Saini SS, Spector S, Rosen KE. Development of a daily diary for patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2010 Aug;105(2):142–148. [PubMed: 20674825]
25.: Mathias SD, Tschosik EA, Zazzali JL. Adaptation and validation of the Urticaria Patient Daily Diary for adolescents. Allergy Asthma Proc. 2012 Mar;33(2):186–190. [PubMed: 22525396]
26.: Mathias SD, Crosby RD, Zazzali JL, Maurer M, Saini SS. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2012 Jan;108(1):20–24. [PubMed: 22192960]
27.: Lennox RD, Leahy MJ. Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol. 2004 Aug;93(2):142–146. [PubMed: 15328673]
28.: Shikiar R, Harding G, Leahy M, Lennox RD. Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria. Health Qual Life Outcomes. 2005;3(36):2005. [PMC free article: PMC1180464] [PubMed: 15907211]
29.: Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210–216. [PubMed: 8033378]
30.: Baiardini I, Pasquali M, Braido F, Fumagalli F, Guerra L, Compalati E, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy. 2005 Aug;60(8):1073–1078. [PubMed: 15969690]
31.: EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199–208. [PubMed: 10109801]
32.: Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011 Sep;128(3):567–573. [PubMed: 21762974]
33.: Maurer M, Altrichter S, Bieber T, Biedermann T, Brautigam M, Seyfried S, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011 Jul;128(1):202–209. [PubMed: 21636116]
34.: Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005 Jul;43(7):736–749. [PubMed: 15970790]
35.: Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005 Aug;14(6):1523–1532. [PubMed: 16110932]
36.: Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008 Nov;159(5):997–1035. [PubMed: 18795920]
37.: Mlynek A, Magerl M, Hanna M, Lhachimi S, Baiardini I, Canonica GW, et al. The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy. 2009 Jun;64(6):927–936. [PubMed: 19453340]
38.: Tavakol M, Mohammadinejad P, Baiardini I, Braido F, Gharagozlou M, Aghamohammadi A, et al. The Persian version of the chronic urticaria quality of life questionnaire: factor analysis, validation, and initial clinical findings. Iranian Journal of Allergy Asthma & Immunology. 2014 Aug;13(4):278–285. [PubMed: 24659164]
39.: Kocaturk E, Weller K, Martus P, Aktas S, Kavala M, Sarigul S, et al. Turkish version of the chronic urticaria quality of life questionnaire: cultural adaptation, assessment of reliability and validity. Acta Derm Venereol. 2012 Jul;92(4):419–425. [PubMed: 21918791]
40.: Dias GA, Pires GV, Valle SO, Franca AT, Papi JA, Dortas SD Jr, et al. Cross-cultural adaptation of the Brazilian-Portuguese version of the chronic urticaria quality-of-life questionnaire - CU-Q2oL. Allergy. 2011 Nov;66(11):1487–1493. [PubMed: 21899558]
41.: Brzoza Z, Badura-Brzoza K, Mlynek A, Magerl M, Baiardini I, Canonica GW, et al. Adaptation and initial results of the Polish version of the GA(2)LEN chronic urticaria quality of life questionnaire (CU-Q(2)oL). J Dermatol Sci. 2011 Apr;62(1):36–41. [PubMed: 21333502]
42.: Valero A, Herdman M, Bartra J, Ferrer M, Jauregui I, Davila I, et al. Adaptation and validation of the Spanish version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). J Investig Allergol Clin Immunol. 2008;18(6):426–432. [PubMed: 19123433]

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK362691

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Omalizumab (Xolair): Treatment of Adults and Adolescents (12 Years of Age and above) with Chronic Idiopathic Urticaria [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug. REFERENCES.